S1. Supplementary Material – Summary statistics

Figure S1 - Directed Acyclic Graph of hypothesised causal structure.




Table S1 - Summary of the longitudinal cohort studies within the UK-LLC

Study ID	Full Study Name	Description	First Survey	Last Survey	Numb er of pande micSu rvey Waves used
ALSPAC	Avon Longitudinal Study of Parents and Children	The children (and some of their mothers) of women who were pregnant between Apr 1991 Dec 1992 in South West England. ¹⁸¹⁹	Apr-May 20	Nov20- Mar21	4
BCS70*	British Cohort Study 1970	Children born in the UK in one week in 1970, with regular follow-up surveys from birth. ²⁰	May-20	Feb/ Mar-21	3
BIB	Born in Bradford	Pregnant women (& partners) recruited at Royal Bradford Infirmary between 2007-2011. ²¹²²	Apr-Jun 20	Oct-Dec 20	2
COPING	COVID-19 Psychiatry and Neurological Genetics Study	Aged 16+ recruited from existing cohorts hosted by NIHR BioResource (GLAD, the Eating Disorders Genetics Initiative (EDGI)). ²³	Apr-20	Apr-20	1
ELSA	English Longitudinal Study of Ageing	Nationally representative pop aged 50+, in private households in England, includes biennial surveys, periodic refreshing of sample. ²⁴	June/Jul 2020	Nov/Dec 2020	2
EXCEED	Extended Cohort for E-health, Environment and DNA	Cohort aged 40-69 recruited 2013+, from the general population through general practices in Leicestershire and Rutland. ^{25 26}	Apr 21	Apr 21	1
GENSCOT	Generation Scotland	A family-based genetic epidemiology study of volunteers from across Scotland, aged 18+. ²⁷	May-20	Mar-21	3
GLAD	Genetic Links to Anxiety and Depression	Participants with depression and/or anxiety aged 16+, invited via media campaigns and recruited online into the NIHR BioResource. ²⁸	Apr-20	Apr-20	1
MCS*	Millennium Cohort Study	UK children born Sep 2000 - Jan 2002, with regular follow-up surveys from birth. ²⁹	May-20	Feb/Mar- 21	3
NCDS58*	National Child Development Study 1958	UK Children born in one week in 1958, with regular follow-up surveys from birth. ³⁰	May-20	Feb/Mar- 21	3
NextSteps*	Next Steps 1989	Recruited via secondary schools in England at age 13, regular follow-up surveys thereafter. ³¹	May-20	Feb/Mar- 21	3
NICOLA	Northern Ireland Cohort for the Longitudinal Study of Ageing	aged 50+, recruited 2012+. Randomized sample of NI addresses from Business Service Organization (BSO) GP Register Database. ³²	Feb-Mar 20	Feb-Mar 20	1
TWINSUK	Twins UK study	Volunteer adult twins (55% monozygotic/43% dizygotic) from UK aged 18+. ³⁴	Apr-May 20	Oct-Nov 20	3
UKHLS	The UK Household Longitudinal Study (Understanding Society)	A nationally representative longitudinal household panel survey, based on a clustered-stratified probability sample of UK households, with participants surveyed annually. ³⁵	Apr-20	Mar-21	8

*Age homogenous cohorts: participants all born in the same year or week of the same year

Table S2 - List of the models tested in the study with exposure modalities and sample subsets.

Model	Exposure	Modalities	Sample subset
	Unomployed	(1) Unemployed	
1	Unemployed	(0) Employed	
T	Retired	(1) Retired	
	Retireu	(0) Employed	
	Part-time	(1) Part-time	All respondents aged 18-66
	Part-time	(2) Full-time	
2	Employed	(1) Employed but not working	
2	not working	(0) Full-time	
	Unemployed	(1) Unemployed	
	Unemployed	(0) Full-time	
	Retired	(1) Retired	
	Retireu	(0) Full-time	
3	Key worker	(1) key worker	
5	Key WOIKEI	(0) Not key worker	
	Partial home	(1) Partial home working	Respondents employed aged 18-66 i.e.
4	working	(0) no home working	self-defined as employed, self- employed, or looking for work
4	No home	(1) Full-time home working	employed, or looking for work
	working	(0) no home working	
5	Furlough	(1) Furlough	
ر ر	Fullougil	(0) Not Furlough	

Study/Sub-Cohort	Self-repo	rt infection		Positive Test Only	Linked Po	sitive Test	Total	No
_	Yes	Missing	Yes	Missing	Yes	Missing	Responses	Individuals
ALSPAC - Combined	2681(21.1)	-	695(5.5)	-	227(1.8)	-	12,685	4592
ALSPAC - Members	2362(21.7)	-	629(5.8)	-	204(1.9)	-	10,909	
ALSPAC - Mothers	321(18.1)	-	53(3.0)	-	23(1.3)	-	1,776	
BCS70	1655(12.2)	84(0.6)	445(3.3)	84(0.6)	255(1.9)	-	13,569	6379
BIB	274(8.5)	-	92(2.84)	-	206(6.4)	-	3,238	1619
COPING	-	10446(100)	-	10446(100)	42(0.4)	-	10,446	10446
ELSA	135(11.8)	-	23(2.0)	-	25(2.2)	-	1,142	571
EXCEED	505(20.0)	-	48(1.9)		30(1.2)		2,471	2462
GENSCOT	798(12.2)	17(0.3)	280(4.3)	102(1.6)	-	6519(100)	6,519	2809
GLAD	-	11786(100)	-	11786(100)	49(0.4)	-	11,786	11786
MCS - Combined	3139(13.7)	206(0.9)	1125(4.9)	206(0.9)	560(2.4)	-	22,988	12427
MCS Members	1560(15.6)	138(1.4)	611(6.1)	138(1.4)	326(3.3)	-	9,980	
MCS Parents	1579(12.1)	68(0.5)	514(4.0)	68(0.5)	234(1.8)	-	13,008	
NCDS58	1319(8.1)	66(0.4)	362(2.2)	66(0.4)	198(1.2)	-	16,383	6963
NextSteps	1247(15.4)	112(1.4)	413(5.1)	112(1.4)	208(2.6)	-	8,084	4224
NICOLA	293(30.4)	-	56(5.8)	636(66.0)	-	963(100)	963	963
TWINSUK	1196(16.4)	69(0.9)	976(13.4)	69(0.9)	881(12.1)	-	7,292	3294
UKHLS	1941(3.9)	5592(11.2)	475(1.0)	5592(11.2)	372(0.7)	-	49,736	6217
Total	15174(9.1)	28378(17.0)	4970(3.0)	29099(17.4)	3053(1.8)	7482(4.5)	167,302	72290

Table S3 – COVID-19 Infection summary statistics by cohort study

Table S4 - Cross tabulated self-reported infection, self-reported positive test, and EPR linked positive test.

		Self-rep	orted Posit	ive Test	
		No	Yes	Missing	Total
Self-reported	No	122,851	395	504	123,750
Infection	Yes	10,382	4,575	217	15,174
_	Missing	-	-	28,378	28,378
	Total	133,233	4,970	29,099	167,302
		Linke	ed Positive	Test	
		No	Yes	Missing	Total
Self-reported	No	115,979	1,397	6,374	123,750
Infection	Yes	12,615	1,468	1,091	15,174
_	Missing	28,173	188	17	28,378
	Total	156,767	3 <i>,</i> 053	7,482	167,302
		Self-rep	orted Posit	ive Test	
		No	Yes	Missing	Total
Linked Positive Test	No	125,242	3,352	28,173	156,767
	Yes	1,583	1,282	188	3,053
_	Missing	6,408	336	738	7,482
	Total	133,233	4,970	29,099	167,302

Table S5 – Self-reported infection, self-reported positive test, and EPR linked positive test rates by time-tranche (Apr-Jun2020, Jul-Oct2020, and Nov-Mar2021) and reduced time-tranche (Apr-Oct2020/Nov-Mar2021).

	Self-Repo	orted	Self-Reporte	ed Positive		
Time-Tranche	Infecti	on	Tes	st	Linked Pos	itive Test
	Yes	Total	Yes	Total	Yes	Total
Apr20-Jun20	4201(9.1)	46,180	582(1.3)	46,180	190(0.3)	67,070
Jul20-Oct20	4263(9.8)	43,307	1241(2.9)	43,222	1210(2.8)	43,609
Nov20-Mar21	6417(13.3)	48,290	3091(6.4)	48,290	1653(3.4)	48,957
Total	14881(10.8)	137,777	4914(3.6)	137,692	3053(1.9)	159,820
Total (inc NICOLA)	15174(10.9)	138924	4970(3.6)	138,203	-	-
Reduced Time-						
tranche	Yes	Total	Yes	Total	Yes	Total
Apr20-Oct20	8464(9.5)	89 <i>,</i> 487	1823(2.0)	89,402	1400(1.3)	110,679
Nov20-Mar21	6417(13.3)	48,290	3091(6.4)	48,290	1653(3.4)	48,957
Total	14881(10.8)	137,777	4914(3.6)	137,692	3053(1.9)	159,820
Total (inc NICOLA)	15174(10.9)	138924	4970(3.6)	138,203	-	-

	-				-				-			
Self-reported Infection/Time-	Ma	Time-t rch 2020 ·	ranche 1 · Octobe		N	Time Tr ov 2020 -	anche-2 March 2	021	М	arch 2020	eriod - March ICOLA)	2021
tranche	Solf	oportod		ed Test	Solf	norted		ed Test sult	Solf	oportod		ed Test
Age at March	Sell-re	eported	K	esult	Sell-re	eported	Re	suit	Self-reported		K	esult
2020	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total
18-34	12.1	23,764	1.4	30,268	20.2	15,146	3.9	15,836	15.3	38,910	2.3	46,104
35-44	8.2	8,974	2.1	12,963	6.5	3,458	3.7	3,753	7.7	12,432	2.5	16,716
45-54	9.1	20,568	1.2	25,601	11	10,576	3.3	10,750	9.8	31,144	1.8	36,351
55-66	7.6	27,710	1	33,340	8.2	14,085	2.6	13,561	7.8	41,795	1.5	46,901
Total	9.4	81,016	1.3	102,172	13	43,265	3.3	43,900	10.6	124,281	1.9	146,072
Sex	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total
Female	9.9	57,600	1.6	72,724	13.7	29,583	3.8	29,807	11.2	87,183	2.2	102,531
Male	8.5	30,004	0.6	36,049	12.6	18,702	2.7	19,143	10.1	48,706	1.4	55,192
Total	9.4	87,604	1.3	108,773	13.3	48,285	3.4	48,950	10.8	135,889	1.9	157,723
Ethnicity	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total
White	9.3	77,604	1.2	94,892	13.1	42,400	3.3	42,729	10.6	120,004	1.9	137,621
Other	9.6	6,990	2.2	10,791	16.3	3,421	4.5	3,706	11.8	10,411	2.8	14,497
Total	9.3	84,594	1.3	105,683	13.3	45,821	3.4	46,435	10.7	130,415	1.9	152,118
Housing Location	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total
Urban	5	20731	>0.10	23274	5	12489	<2.26	14144	5	33220	0.9	37418
Rural	3.7	6960	<0.15	7657	2.7	4202	>0.90	4643	3.3	11162	0.4	12300
Total	4.7	27691	0.1	30931	4.4	16691	1.9	18787	4.6	44382	0.8	49718
Housing Composition	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total
Partner+Kids	9.6	24797	1.9	23154	11.4	12707	3.5	12167	10.2	37504	2.5	35321
Partner Only	9	34724	0.8	32993	12.8	19110	3.2	18474	10.3	53834	1.7	51467
Single parent	11.3	4422	2	4197	14.5	2370	4.5	2299	12.4	6792	2.9	6496
Other	8.7	14104	1.7	14203	17.6	8189	3.5	8283	12	22293	2.4	22486
Alone	10.1	6149	0.7	5528	7.5	3523	2.5	3280	9.1	9672	1.4	8808
Total	9.3	84196	1.3	80075	12.9	45899	3.4	44503	10.6	130095	2.1	124578
Vaccinations	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total	%Yes	Total
None	>9.0	84744	>1.5	88425	<14	30594	<3.0	32863	10.4	115338	1.9	121288
One or more	<50	22	<50	22	>14	15915	>4.1	16094	13.1	15937	4.2	16116
Total	9.3	84766	1.5	88447	13.2	46509	3.4	48957	10.7	131275	2.2	137404

Table S5 – Self-reported and linked infection rates for Essential occupation by time-tranche, and full study period

				Self-Rep	ortea				Linked P	ositive		
Analysis Comparison	Model	Time_Tranche	RR(95%.C.I.)	Q(p-val)	Tau2	12	H2	RR(95%.C.I.)	Q(p-val)	Tau2	12	H2
Employed?(Unemp v Emp)	Unadj	Overall	0.89(0.80,1.00)	0.000	0.03	76.9	4.32	0.82(0.69,0.97)	0.143	0.03	40.1	1.67
Employed?(Unemp v Emp)	Unadj	Apr-Oct20	0.86(0.80,0.92)	0.013	0.00	0.0	1.00	0.97(0.88,1.06)	0.136	0.00	0.0	1.00
Employed?(Unemp v Emp)	Unadj	Nov-Mar21	0.91(0.81,1.02)	0.001	0.02	58.9	2.43	0.76(0.66,0.87)	0.957	0.00	0.0	1.00
Employed?(Unemp v Emp)	Adj Mod1	Overall	0.89(0.79,1.00)	0.000	0.03	78.3	4.62	0.82(0.72,0.92)	0.831	0.00	0.0	1.00
Employed?(Unemp v Emp)	Adj Mod1	Apr-Oct20	0.85(0.79,0.91)	0.012	0.00	0.0	1.00	0.78(0.61,1.01)	0.109	0.05	43.8	1.78
Employed?(Unemp v Emp)	Adj Mod1	Nov-Mar21	0.91(0.81,1.02)	0.001	0.02	57.7	2.37	0.75(0.65,0.86)	0.881	0.00	0.0	1.00
Employed?(Unemp v Emp)	Adj Mod2	Overall	0.90(0.81,1.00)	0.000	0.02	69.7	3.30	0.81(0.71,0.91)	0.696	0.00	0.0	1.00
Employed?(Unemp v Emp)	Adj Mod2	Apr-Oct20	0.85(0.79,0.92)	0.016	0.00	0.0	1.00	0.77(0.60,0.98)	0.126	0.05	41.7	1.71
Employed?(Unemp v Emp)	Adj Mod2	Nov-Mar21	0.92(0.80,1.05)	0.000	0.03	68.7	3.20	0.76(0.66,0.87)	0.929	0.00	0.0	1.00
Employed?(Retired v Emp)	Unadj	Overall	0.86(0.66,1.11)	0.000	0.10	85.4	6.85	0.55(0.42,0.73)	0.635	0.00	0.0	1.00
Employed?(Retired v Emp)	Unadj	Apr-Oct20	0.87(0.62,1.22)	0.000	0.14	87.3	7.86	0.63(0.29,1.36)	0.008	0.38	71.0	3.45
Employed?(Retired v Emp)	Unadj	Nov-Mar21	1.03(0.52,2.04)	0.000	0.68	97.1	34.68	0.59(0.40,0.87)	0.453	0.00	0.0	1.00
Employed?(Retired v Emp)	Adj Mod1	Overall	0.88(0.72,1.08)	0.000	0.06	75.9	4.15	0.57(0.43,0.75)	0.715	0.00	0.0	1.00
Employed?(Retired v Emp)	Adj Mod1	Apr-Oct20	0.94(0.69,1.28)	0.000	0.11	82.9	5.86	0.66(0.30,1.46)	0.011	0.40	70.9	3.44
Employed?(Retired v Emp)	Adj Mod1	Nov-Mar21	1.11(0.60,2.05)	0.000	0.55	96.2	26.57	0.60(0.40,0.88)	0.682	0.00	0.0	1.00
Employed?(Retired v Emp)	Adj Mod2	Overall	0.88(0.73,1.04)	0.001	0.04	65.7	2.92	0.58(0.44,0.77)	0.772	0.00	0.0	1.00
Employed?(Retired v Emp)	Adj Mod2	Apr-Oct20	0.94(0.66,1.34)	0.000	0.12	84.7	6.55	0.86(0.45,1.64)	0.136	0.19	50.3	2.01
Employed?(Retired v Emp)	Adj Mod2	Nov-Mar21	1.34(0.57,3.18)	0.000	0.91	95.3	21.35	0.62(0.42,0.92)	0.657	0.00	0.0	1.00
Emp Status(Part-time v FT)	Unadj	Overall	0.95(0.90,1.00)	0.661	0.00	0.0	1.00	0.86(0.69,1.06)	0.056	0.05	47.6	1.91
Emp Status(Part-time v FT)	Unadj	Apr-Oct20	0.87(0.79,0.95)	0.317	0.00	20.5	1.26	0.63(0.47,0.85)	0.467	0.02	10.3	1.11
Emp Status(Part-time v FT)	Unadj	Nov-Mar21	0.98(0.86,1.11)	0.023	0.02	52.9	2.12	0.95(0.78,1.17)	0.428	0.01	15.0	1.18
Emp Status(Part-time v FT)	Adj Mod1	Overall	0.94(0.89,0.99)	0.480	0.00	0.0	1.00	0.82(0.65,1.04)	0.020	0.08	55.8	2.26
Emp Status(Part-time v FT)	Adj Mod1	Apr-Oct20	0.86(0.78,0.94)	0.254	0.00	20.9	1.26	0.59(0.43,0.81)	0.549	0.03	14.0	1.16
Emp Status(Part-time v FT)	Adj Mod1	Nov-Mar21	0.96(0.85,1.09)	0.033	0.02	50.8	2.03	0.92(0.73,1.14)	0.261	0.03	27.8	1.38
Emp Status(Part-time v FT)	Adj Mod2	Overall	0.96(0.90,1.02)	0.284	0.00	16.3	1.19	0.89(0.71,1.11)	0.141	0.05	41.5	1.71
Emp Status(Part-time v FT)	Adj Mod2	Apr-Oct20	0.87(0.79,0.95)	0.190	0.00	23.8	1.31	0.68(0.50,0.93)	0.722	0.00	0.0	1.00
Emp Status(Part-time v FT)	Adj Mod2	Nov-Mar21	0.97(0.86,1.09)	0.053	0.01	47.2	1.89	0.90(0.72,1.13)	0.347	0.03	23.2	1.30
Emp Status(Emp but not wking v FT)	Unadj	Overall	0.99(0.89,1.11)	0.000	0.03	71.7	3.54	1.05(0.81,1.35)	0.001	0.10	60.4	2.53
Emp Status(Emp but not wking v FT)	Unadj	Apr-Oct20	0.92(0.75,1.13)	0.000	0.09	85.6	6.92	0.93(0.66,1.30)	0.055	0.03	10.6	1.12

Table S6 – Stage 2 combined results of Individual Patient Data meta-analysis, including heterogeneity statistics

Emp Status(Emp but not wking v FT)	Unadj	Nov-Mar21	1.06(0.91,1.23)	0.001	0.04	71.3	3.48	1.08(0.81,1.43)	0.008	0.10	56.9	2.32
Emp Status(Emp but not wking v FT)	Adj Mod1	Overall	0.99(0.88,1.11)	0.000	0.03	72.4	3.62	1.03(0.79,1.33)	0.001	0.10	59.9	2.49
Emp Status(Emp but not wking v FT)	Adj Mod1	Apr-Oct20	0.92(0.75,1.13)	0.000	0.10	85.6	6.93	0.90(0.68,1.20)	0.071	0.00	0.0	1.00
Emp Status(Emp but not wking v FT)	Adj Mod1	Nov-Mar21	1.05(0.90,1.22)	0.001	0.04	70.7	3.41	1.05(0.79,1.40)	0.010	0.09	55.7	2.26
Emp Status(Emp but not wking v FT)	Adj Mod2	Overall	0.98(0.88,1.09)	0.000	0.02	68.5	3.18	1.02(0.80,1.29)	0.006	0.07	52.4	2.10
Emp Status(Emp but not wking v FT)	Adj Mod2	Apr-Oct20	0.92(0.74,1.15)	0.000	0.10	86.2	7.27	0.85(0.63,1.15)	0.288	0.00	0.0	1.00
Emp Status(Emp but not wking v FT)	Adj Mod2	Nov-Mar21	1.03(0.88,1.21)	0.002	0.04	70.6	3.40	1.05(0.81,1.38)	0.029	0.08	50.1	2.00
Emp Status(Unempl v FT)	Unadj	Overall	0.85(0.73,1.00)	0.000	0.06	84.5	6.46	0.75(0.61,0.92)	0.032	0.05	48.9	1.96
Emp Status(Unempl v FT)	Unadj	Apr-Oct20	0.75(0.63,0.90)	0.000	0.07	75.6	4.09	0.53(0.30,0.94)	0.000	0.45	68.1	3.13
Emp Status(Unempl v FT)	Unadj	Nov-Mar21	0.91(0.81,1.03)	0.020	0.02	55.2	2.23	0.74(0.63,0.87)	0.776	0.00	0.0	1.00
Emp Status(Unempl v FT)	Adj Mod1	Overall	0.85(0.72,1.01)	0.000	0.07	85.9	7.11	0.73(0.62,0.86)	0.434	0.01	17.5	1.21
Emp Status(Unempl v FT)	Adj Mod1	Apr-Oct20	0.74(0.61,0.90)	0.000	0.07	76.1	4.19	0.53(0.31,0.90)	0.000	0.35	60.6	2.54
Emp Status(Unempl v FT)	Adj Mod1	Nov-Mar21	0.91(0.80,1.02)	0.031	0.02	52.5	2.11	0.71(0.61,0.84)	0.693	0.00	0.0	1.00
Emp Status(Unempl v FT)	Adj Mod2	Overall	0.84(0.72,0.97)	0.000	0.05	81.4	5.39	0.72(0.63,0.83)	0.599	0.00	0.0	1.00
Emp Status(Unempl v FT)	Adj Mod2	Apr-Oct20	0.76(0.62,0.93)	0.001	0.07	75.6	4.10	0.56(0.37,0.85)	0.188	0.11	30.5	1.44
Emp Status(Unempl v FT)	Adj Mod2	Nov-Mar21	0.91(0.79,1.06)	0.002	0.03	67.2	3.05	0.73(0.62,0.87)	0.715	0.00	0.0	1.00
Emp Status(Retired v FT)	Unadj	Overall	0.80(0.62,1.02)	0.000	0.10	81.3	5.35	0.54(0.34,0.87)	0.008	0.18	73.4	3.75
Emp Status(Retired v FT)	Unadj	Apr-Oct20	0.75(0.56,1.01)	0.000	0.14	82.1	5.59	0.87(0.64,1.20)	0.109	0.05	58.0	2.38
Emp Status(Retired v FT)	Unadj	Nov-Mar21	0.98(0.56,1.69)	0.000	0.57	96.3	27.16	0.64(0.47,0.86)	0.521	0.00	0.0	1.00
Emp Status(Retired v FT)	Adj Mod1	Overall	0.80(0.66,0.98)	0.001	0.06	69.8	3.31	0.58(0.38,0.90)	0.020	0.13	67.6	3.08
Emp Status(Retired v FT)	Adj Mod1	Apr-Oct20	0.79(0.61,1.03)	0.001	0.10	75.1	4.01	0.91(0.66,1.27)	0.158	0.07	56.5	2.30
Emp Status(Retired v FT)	Adj Mod1	Nov-Mar21	1.08(0.66,1.79)	0.000	0.46	95.2	20.91	0.69(0.48,1.01)	0.358	0.03	17.2	1.21
Emp Status(Retired v FT)	Adj Mod2	Overall	0.81(0.68,0.96)	0.004	0.04	59.5	2.47	0.71(0.54,0.94)	0.384	0.03	30.4	1.44
Emp Status(Retired v FT)	Adj Mod2	Apr-Oct20	0.82(0.64,1.06)	0.001	0.09	72.6	3.65	1.02(0.86,1.19)	0.603	0.00	5.8	1.06
Emp Status(Retired v FT)	Adj Mod2	Nov-Mar21	1.21(0.63,2.30)	0.000	0.67	93.2	14.63	0.73(0.48,1.11)	0.287	0.05	26.6	1.36
Home wking(Some hm wrk vs all)	Unadj	Overall	1.06(0.97,1.17)	0.188	0.01	38.0	1.61	1.40(1.16,1.70)	0.632	0.00	0.0	1.00
Home wking(Some hm wrk vs all)	Unadj	Apr-Oct20	1.04(0.92,1.17)	0.170	0.01	40.8	1.69	1.84(0.96,3.52)	0.021	0.45	63.1	2.71
Home wking(Some hm wrk vs all)	Unadj	Nov-Mar21	1.08(0.95,1.23)	0.022	0.02	52.3	2.10	1.35(1.11,1.66)	0.477	0.00	0.0	1.00
Home wking(Some hm wrk vs all)	Adj Mod1	Overall	1.06(0.97,1.17)	0.233	0.01	35.2	1.54	1.39(1.14,1.69)	0.647	0.00	0.0	1.00
Home wking(Some hm wrk vs all)	Adj Mod1	Apr-Oct20	1.04(0.92,1.17)	0.206	0.01	39.2	1.64	1.96(0.92,4.16)	0.013	0.63	62.3	2.65
Home wking(Some hm wrk vs all)	Adj Mod1	Nov-Mar21	1.08(0.95,1.23)	0.032	0.02	50.6	2.02	1.33(1.08,1.63)	0.499	0.00	0.0	1.00
Home wking(Some hm wrk vs all)	Adj Mod2	Overall	1.08(1.01,1.16)	0.574	0.00	2.8	1.03	1.40(1.15,1.71)	0.591	0.00	0.0	1.00
Home wking(Some hm wrk vs all)	Adj Mod2	Apr-Oct20	1.04(0.93,1.17)	0.366	0.01	24.1	1.32	1.76(0.90,3.44)	0.010	0.57	66.1	2.95

Home wking(Some hm wrk vs all)	Adj Mod2	Nov-Mar21	1.11(0.99,1.24)	0.173	0.01	32.5	1.48	1.33(1.08,1.64)	0.490	0.00	0.0	1.00
Home wking(Non hm wrk v all)	Unadj	Overall	1.08(0.98,1.19)	0.001	0.01	64.6	2.82	1.79(1.44,2.23)	0.038	0.06	51.1	2.05
Home wking(Non hm wrk v all)	Unadj	Apr-Oct20	1.05(0.93,1.18)	0.000	0.02	68.0	3.12	2.98(1.80,4.92)	0.003	0.30	67.5	3.07
Home wking(Non hm wrk v all)	Unadj	Nov-Mar21	1.09(0.94,1.27)	0.000	0.04	79.4	4.84	1.63(1.33,2.00)	0.161	0.03	34.3	1.52
Home wking(Non hm wrk v all)	Adj Mod1	Overall	1.08(0.98,1.19)	0.001	0.02	66.9	3.02	1.78(1.42,2.22)	0.015	0.06	52.2	2.09
Home wking(Non hm wrk v all)	Adj Mod1	Apr-Oct20	1.04(0.93,1.18)	0.000	0.02	66.7	3.00	3.13(1.81,5.42)	0.001	0.36	68.8	3.20
Home wking(Non hm wrk v all)	Adj Mod1	Nov-Mar21	1.11(0.95,1.28)	0.000	0.04	77.3	4.40	1.64(1.37,1.96)	0.196	0.01	17.6	1.21
Home wking(Non hm wrk v all)	Adj Mod2	Overall	1.03(0.91,1.16)	0.000	0.03	76.8	4.31	1.77(1.40,2.25)	0.025	0.07	55.3	2.24
Home wking(Non hm wrk v all)	Adj Mod2	Apr-Oct20	1.04(0.91,1.19)	0.000	0.03	68.5	3.17	3.23(1.76,5.93)	0.000	0.49	73.8	3.82
Home wking(Non hm wrk v all)	Adj Mod2	Nov-Mar21	1.16(1.01,1.32)	0.001	0.03	68.7	3.19	1.62(1.35,1.96)	0.240	0.02	21.1	1.27
Keyworker (Yes v No)	Unadj	Overall	1.24(1.17,1.32)	0.040	0.00	39.6	1.66	1.87(1.55,2.26)	0.000	0.07	66.2	2.96
Keyworker (Yes v No)	Unadj	Apr-Oct20	1.21(1.14,1.28)	0.573	0.00	0.0	1.00	2.30(1.58,3.36)	0.000	0.27	76.0	4.16
Keyworker (Yes v No)	Unadj	Nov-Mar21	1.30(1.16,1.46)	0.000	0.02	67.1	3.04	1.57(1.36,1.81)	0.308	0.01	13.6	1.16
Keyworker (Yes v No)	Adj Mod1	Overall	1.24(1.17,1.32)	0.045	0.00	37.3	1.59	1.85(1.56,2.20)	0.000	0.05	58.0	2.38
Keyworker (Yes v No)	Adj Mod1	Apr-Oct20	1.19(1.12,1.27)	0.469	0.00	2.3	1.02	2.32(1.55,3.49)	0.000	0.33	70.8	3.43
Keyworker (Yes v No)	Adj Mod1	Nov-Mar21	1.30(1.16,1.46)	0.000	0.02	65.5	2.90	1.64(1.42,1.90)	0.551	0.00	0.0	1.00
Keyworker (Yes v No)	Adj Mod2	Overall	1.24(1.18,1.31)	0.191	0.00	17.3	1.21	1.65(1.45,1.87)	0.187	0.01	25.6	1.34
Keyworker (Yes v No)	Adj Mod2	Apr-Oct20	1.17(1.10,1.26)	0.204	0.00	15.3	1.18	1.77(1.25,2.51)	0.011	0.17	55.7	2.26
Keyworker (Yes v No)	Adj Mod2	Nov-Mar21	1.32(1.16,1.49)	0.000	0.03	67.9	3.12	1.61(1.37,1.89)	0.393	0.01	8.2	1.09
Furlough (Yes v No)	Unadj	Overall	0.93(0.88,0.99)	0.482	0.00	0.0	1.00	0.83(0.68,1.00)	0.737	0.00	0.0	1.00
Furlough (Yes v No)	Unadj	Apr-Oct20	0.84(0.72,0.98)	0.001	0.04	66.5	2.99	0.76(0.52,1.11)	0.510	0.00	0.0	1.00
Furlough (Yes v No)	Unadj	Nov-Mar21	1.03(0.94,1.12)	0.479	0.00	0.0	1.00	0.83(0.66,1.05)	0.604	0.00	1.0	1.01
Furlough (Yes v No)	Adj Mod1	Overall	0.93(0.88,0.99)	0.370	0.00	0.0	1.00	0.80(0.66,0.98)	0.849	0.00	0.0	1.00
Furlough (Yes v No)	Adj Mod1	Apr-Oct20	0.84(0.72,0.98)	0.001	0.05	67.0	3.03	0.78(0.53,1.14)	0.594	0.00	0.0	1.00
Furlough (Yes v No)	Adj Mod1	Nov-Mar21	1.02(0.93,1.11)	0.561	0.00	0.0	1.00	0.80(0.64,1.01)	0.824	0.00	0.0	1.00
Furlough (Yes v No)	Adj Mod2	Overall	0.90(0.85,0.96)	0.727	0.00	0.0	1.00	0.82(0.67,1.01)	0.835	0.00	0.0	1.00
Furlough (Yes v No)	Adj Mod2	Apr-Oct20	0.84(0.72,0.98)	0.001	0.05	66.0	2.94	0.77(0.53,1.13)	0.600	0.00	0.0	1.00
Furlough (Yes v No)	Adj Mod2	Nov-Mar21	0.97(0.88,1.05)	0.707	0.00	0.0	1.00	0.82(0.65,1.04)	0.691	0.00	0.0	1.00

S7. Appendices – Example Forest-plots (Furlough vs Not)

(%)

0.63

5.97

5.03

3.92

4.82

0.83

2.31

1.88

3.14

4.60

8.75

0.52

4.95

3.73

3.09

2.69

0.91

1.78

1.10

5.41

1.43

0.08

3.58

2.64

3.70

1.76

2 86

3.38

1.21

exp(Furlough v not) Weight Study with 95% CI Overall 0.84 [0.43, 1.62] ELSA UKHLS 0.99 [0.83, 1.16] BCS70 0.99 [0.82, 1.20] NCDS58 0.87 [0.69, 1.10] NextSteps 0.84 [0.69, 1.02] BIB 0.56 [0.32, 1.00] GENSCOT 1.03 [0.75, 1.43] NICOLA 0.90 [0.62, 1.29] MCS-Member 0.82 [0.63, 1.07] MCS-Parents 0.95 [0.77, 1.17] ALSPAC-Mem 0.95 [0.85, 1.07] ALSPAC-Mothers 1.06 [0.76, 1.49] 2.13 Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$ 0.93 [0.88, 0.99] Test of $\theta_i = \theta_j$: Q(11) = 7.34, p = 0.77 Apr-Oct20 ELSA 0.94 [0.45, 1.95] UKHLS 1.27 [1.04, 1.54] BCS70 0.88 [0.69, 1.12] NCDS58 0.79 [0.60, 1.03] NextSteps 0.73 [0.54, 0.98] BIB 0.51 [0.29, 0.88] GENSCOT 0.86 [0.59, 1.25] MCS-Member 0.42 [0.25, 0.68] MCS-Parents 0.77 [0.58, 1.01] 2.92 ALSPAC-Mem 0.81 [0.68, 0.98] ALSPAC-Mothers 1.48 [0.97, 2.27] Heterogeneity: $\tau^2 = 0.06$, $I^2 = 71.24\%$, $H^2 = 3.48$ 0.83 [0.70, 0.99] Test of $\theta_i = \theta_i$: Q(10) = 35.95, p = 0.00 Nov20-Mar21 ELSA 0.49 [0.07, 3.39] UKHLS 0.98 [0.70, 1.39] 2.10 BCS70 1.00 [0.78, 1.27] NCDS58 0.93 [0.69, 1.25] NextSteps 0.86 [0.68, 1.09] GENSCOT 1.08 [0.74, 1.57] MCS-Member 0.91 [0.69, 1.21] MCS-Parents 1.05 [0.81, 1.36] ALSPAC-Mem 1.04 [0.88, 1.22] 6.18 ALSPAC-Mothers 1.07 [0.67, 1.71] Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$ 0.99 [0.90, 1.07] Test of $\theta_i = \theta_j$: Q(9) = 3.22, p = 0.96

1/2 0.6

0.8 1 1.2 1.4 1.6 1.8 2 2.22.4

Self-reported – Unadjusted models

Test of group differences: $Q_b(2) = 2.97$, p = 0.23

Random-effects ML model

Self-reported – Adjusted models

Study		exp(Furlough v not) with 95% Cl	Weight (%)
Overall			. ,
ELSA	← ■	0.87 [0.44, 1.69]	0.68
UKHLS		0.99 [0.84, 1.17]	5.90
BCS70		0.99 [0.82, 1.21]	5.12
NCDS58	_	0.88 [0.70, 1.11]	4.10
NextSteps		0.82 [0.67, 1.01]	4.81
BIB		0.53 [0.29, 0.99]	0.80
GENSCOT		1.10 [0.76, 1.59]	2.00
NICOLA		0.90 [0.62, 1.30]	1.98
MCS-Member		0.84 [0.64, 1.09]	3.30
MCS-Parents		0.92 [0.73, 1.14]	4.28
ALSPAC-Mem		0.96 [0.86, 1.08]	8.18
ALSPAC-Mothers		1.06 [0.76, 1.49]	2.28
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$		0.94 [0.88, 1.00]	2.20
Test of $\theta_i = \theta_j$: Q(11) = 8.09, p = 0.71			
Apr-Oct20			
ELSA	← ■	0.97 [0.47, 2.01]	0.58
UKHLS	· · · · · · · · · · · · · · · · · · ·	1.29 [1.06, 1.56]	5.00
BCS70		0.90 [0.71, 1.14]	3.88
NCDS58	·	0.80 [0.61, 1.05]	3.24
NextSteps		0.70 [0.52, 0.95]	2.82
BIB	←───	0.49 [0.26, 0.89]	0.82
GENSCOT		0.94 [0.62, 1.43]	1.62
MCS-Member	←──	0.43 [0.26, 0.71]	1.20
MCS-Parents		0.74 [0.55, 1.00]	2.85
ALSPAC-Mem		0.82 [0.68, 0.99]	5.36
ALSPAC-Mothers		1.46 [0.96, 2.23]	1.60
Heterogeneity: $\tau^2 = 0.07$, $I^2 = 74.36\%$, $H^2 = 3.90$		0.84 [0.70, 1.02]	
Test of $\theta_i = \theta_j$: Q(10) = 35.84, p = 0.00			
Nov20-Mar21			
ELSA	< →	0.53 [0.08, 3.56]	0.09
UKHLS		0.99 [0.70, 1.40]	2.18
BCS70		0.99 [0.77, 1.27]	3.74
NCDS58		0.92 [0.69, 1.24]	2.85
NextSteps		0.84 [0.66, 1.08]	3.78
GENSCOT		1.07 [0.69, 1.67]	1.46
MCS-Member		0.91 [0.69, 1.21]	3.04
MCS-Parents		1.00 [0.76, 1.33]	3.08
ALSPAC-Mem	+ =	1.04 [0.88, 1.23]	6.04
ALSPAC-Mothers		1.02 [0.64, 1.63]	1.35
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$	•	0.97 [0.89, 1.07]	
Test of $\theta_i = \theta_j$: Q(9) = 2.98, p = 0.97			
Test of group differences: $Q_b(2) = 1.91$, p = 0.38			
	1/2 0.6 0.8 1 1.2 1.4 1.6 1.8 2 2.22.4		

Random-effects REML model

Linked positive – Unadjusted models

Study			exp(Furlough v not) with 95% Cl	Weight (%)
Overall				
ELSA	<	\rightarrow	1.57 [0.31, 8.09]	0.82
BCS70	←		0.84 [0.49, 1.46]	7.36
NCDS58	←		0.61 [0.31, 1.21]	4.76
NextSteps			0.86 [0.50, 1.48]	7.53
BIB	·		0.94 [0.51, 1.75]	5.70
COPING	<	\rightarrow	0.64 [0.09, 4.61]	0.56
MCS-Member			0.92 [0.52, 1.63]	6.82
MCS-Parents			0.97 [0.55, 1.71]	6.89
ALSPAC-Mem			0.82 [0.50, 1.34]	9.06
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$			0.86 [0.70, 1.06]	
Test of $\theta_i = \theta_j$: Q(8) = 1.95, p = 0.98				
Apr-Oct20				
ELSA	<		2.37 [0.25, 22.29]	0.44
BCS70			0.52 [0.16, 1.66]	1.62
NCDS58	←		0.17 [0.02, 1.28]	0.55
NextSteps	< ∎		0.85 [0.34, 2.14]	2.57
BIB	←		0.83 [0.44, 1.56]	5.48
COPING	< •	\rightarrow	0.64 [0.09, 4.61]	0.56
MCS-Member	<		0.19 [0.02, 1.44]	0.52
ALSPAC-Mem	← ■	\rightarrow	0.97 [0.36, 2.58]	2.28
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$			0.74 [0.50, 1.09]	
Test of $\theta_i = \theta_j$: Q(7) = 5.69, p = 0.58				
Nov20-Mar21				
ELSA	<	\rightarrow	1.39 [0.19, 10.06]	0.56
BCS70	← ■		0.77 [0.42, 1.41]	5.97
NCDS58	←		0.80 [0.39, 1.62]	4.33
NextSteps	← ■		0.70 [0.37, 1.33]	5.42
MCS-Member	← ■		0.89 [0.49, 1.59]	6.40
MCS-Parents		-	1.16 [0.66, 2.05]	6.92
ALSPAC-Mem	<		0.79 [0.45, 1.39]	6.89
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$			0.86 [0.67, 1.10]	
Test of $\theta_i = \theta_j$: Q(6) = 2.00, p = 0.92				
Test of group differences: $Q_b(2) = 0.50$, p = 0.78				
	1/2 0.6 0.8 1 1.2 1.4 1.6 1.8	2 ^{2.22.4}		

Random-effects REML model

Linked Positive – Adjusted models

Study					exp(Furlough v not) with 95% Cl	Weight (%)
Overall						
ELSA	-				0.53 [0.13, 2.23]	1.05
UKHLS	←	_			0.34 [0.15, 0.77]	3.26
BCS70	←				0.85 [0.49, 1.46]	7.17
NCDS58	←∎				0.61 [0.31, 1.21]	4.65
NextSteps		┿┓┽			0.86 [0.50, 1.48]	7.36
COPING	←			\longrightarrow	0.64 [0.09, 4.61]	0.55
ALSPAC	←				0.77 [0.48, 1.23]	9.83
MCS-Member					0.92 [0.52, 1.63]	6.66
MCS-Parents					0.97 [0.55, 1.71]	6.73
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$					0.77 [0.62, 0.95]	
Test of $\theta_i = \theta_j$: Q(8) = 5.91, p = 0.66		T				
Apr-Oct20						
ELSA	←				0.33 [0.08, 1.37]	1.06
BCS70					0.52 [0.16, 1.66]	1.58
NCDS58	←				0.17 [0.02, 1.28]	0.54
NextSteps	←				0.85 [0.34, 2.14]	2.51
BIB	←				0.83 [0.44, 1.56]	5.35
COPING	←			\longrightarrow	0.64 [0.09, 4.61]	0.55
ALSPAC	←	-		\longrightarrow	0.97 [0.37, 2.58]	2.26
MCS-Member	←				0.19 [0.02, 1.44]	0.51
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$					0.67 [0.46, 0.99]	
Test of $\theta_i = \theta_j$: Q(7) = 5.65, p = 0.58						
Nov20-Mar21						
UKHLS	←				0.39 [0.15, 1.01]	2.37
BCS70	←	•			0.76 [0.42, 1.40]	5.82
NCDS58	←	-			0.80 [0.39, 1.62]	4.24
NextSteps	\leftarrow				0.70 [0.37, 1.33]	5.30
ALSPAC	←				0.73 [0.43, 1.24]	7.64
MCS-Member	←	┿┻┼			0.89 [0.49, 1.59]	6.25
MCS-Parents	-				1.16 [0.66, 2.05]	6.76
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$					0.80 [0.63, 1.01]	
Test of $\theta_i = \theta_j$: Q(6) = 4.28, p = 0.64						
Test of group differences: $Q_b(2) = 0.56$, p = 0.75						
	1/2 0.6	0.8 1	1.2 1.4 1.6 1.	⁸ 2 ^{2.22.4}		
Random-effects REML model						

Random-effects REML model

S8 - Information about Longitudinal Population Studies (LPS) for researchers to include in the Supplementary Materials of their publications

DOC number:	DOC-ISM-032	Version:	V1.1
Author(s):	Katharine Evans, UK LLC Governance & Policy Manager	Date:	27/09/2022
Authorised by:	Andy Boyd, UK LLC Director	Date:	08/11/2022
Date published:	09/11/2022	Date to review:	20/12/2023
Permission to edit this document must be provided by:	Director; Senior Research Manager		

Review History

Version	Review Date	Reviewed by	Section(s) amended	Authorised by
V1.1	20/12/2022	Katharine Evans	Added websites for UKHLS data requests	Andy Boyd, Director

INTRODUCTION

The <u>UK LLC Publication Policy</u> describes the **requirements** for researchers when publishing **papers and similar outputs (such as reports, books and other manuscripts)** based on data accessed in the UK LLC Trusted Research Environment (TRE).

More than 20 LPS provide data to the UK LLC TRE and researchers **must** acknowledge each LPS included in the analyses that underpin their publications – **see the** <u>UK LLC Publication Policy</u> **for the required wording for your Methods and Acknowledgements sections**.

The information in the tables below has been provided by the LPS. Copy the information about each LPS that has contributed to your research and include it in the **Supplementary Materials** section of your publication – **you do not have to present the information in table format**.

LPS INFORMATION (LPS listed in alphabetical order)

ALSPAC: Avon Longitudinal Study	ALSPAC: Avon Longitudinal Study of Parents and Children		
Description of Study Population (including citations and references if required)	Pregnant women resident in a defined area of the former county of Avon, UK with expected dates of delivery 1st April 1991 to 31st December 1992 were invited to take part in the study ^{1,2} . The initial number of pregnancies enrolled is 14,541 (14,676 foetuses), resulting in 14,062 live births and 13,988 children who were alive at 1 year of age. Further recruitment took place after the age of 7 years, the total sample size for analyses using any data collected after the age of 7 is therefore 15,454 pregnancies, resulting in 15,589 foetuses. Of these 14,901 were alive at 1 year of age.		
	¹ Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, Molloy L, Ness A, Ring S, Davey Smith G. Cohort Profile: The 'Children of the 90s'; the index offspring of The Avon Longitudinal Study of Parents and Children (ALSPAC). International Journal of Epidemiology 2013; 42: 111-127.		
	² Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, Henderson J, Macleod J, Molloy L, Ness A, Ring S, Nelson SM, Lawlor DA. Cohort Profile: The Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. International Journal of Epidemiology 2013; 42:97- 110.		
Acknowledgements	We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and		

	the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses.
Ethics	Ethical approval for the study was obtained from the ALSPAC Law and Ethics committee and local research ethics committees (NHS Haydock REC: 10/H1010/70).
Website for Data Requests	http://www.bristol.ac.uk/alspac/researchers/access/

BCS70: 1970 British Cohort Study	
Description of Study Population (including citations and references if required)	The 1970 British Cohort Study (BCS70) follows the lives of more than 17,000 people born in England, Scotland and Wales in a single week of 1970. Over the course of cohort members' lives, BCS70 has collected information on health, physical, educational and social development, and economic circumstances, among other factors.
	Since the birth survey in 1970, there have been nine 'sweeps' of all cohort members at ages 5, 10, 16, 26, 30, 34, 38, 42 and most recently at 46 (a biomedical data collection). The Age 51 Sweep is currently in the field (2022).
	Data have been collected from a number of different sources, including the midwife present at birth, parents of the cohort members, head and class teachers, school health service personnel and the cohort members themselves.
	The data have been collected in a variety of ways, including via paper and electronic questionnaires, clinical records, medical examinations, biological samples, physical measurements, tests of ability, educational assessments and diaries.

	The study is conducted by the Centre for Longitudinal Studies.
Acknowledgements	BCS70 is core-funded by the ESRC.
Ethics	Ethics approval has been obtained for each follow-up from an NHS Research Ethics Committee (REC) since 2000. In addition, separate REC approval is in place to cover the ongoing activities of the study in between major sweeps of data collection (i.e. Keeping in touch with and tracing cohort members; cleaning, documenting and providing access to the data for research; and linking data from administrative sources to survey data to increase the utility of the data for research).
Website for Data Requests	https://cls.ucl.ac.uk/cls-studies/bcs70/

BIB: Born in Bradford	
Description of Study Population	Born in Bradford (BiB) is a prospective pregnancy and birth
(including citations and	cohort study of the children, mothers and fathers from
references if required)	13,776 pregnancies from between 2007 and 2011, based in
	Bradford, UK. The study was established to examine how
	genetic, nutritional, environmental, behavioural and social
	factors affect health and development during childhood, and
	subsequently, adult life in a deprived multi-ethnic
	population ¹ . From 2017 to 2021 a full follow-up of the cohort
	was conducted ² to investigate the determinants of children's
	pre-pubertal health and development, including through
	understanding parents' health and wellbeing, and to obtain
	data on exposures in childhood that might influence future
	health. In 2022, the Age of Wonder study was launched to
	complete another full follow-up through adolescence into
	adulthood, focusing on priority areas of physical and mental
	health, growth, identity, cognition, socioeconomic status and
	environmental exposures.
	¹ John Wright, Neil Small, Pauline Raynor, Derek Tuffnell, Raj
	Bhopal, Noel Cameron, Lesley Fairley, Debbie A Lawlor, Roger
	Parslow, Emily S Petherick, Kate E Pickett, Dagmar

	Waiblinger, Jane West, on behalf of the Born in Bradford Scientific Collaborators Group, Cohort Profile: The Born in Bradford multi-ethnic family cohort study, International Journal of Epidemiology, Volume 42, Issue 4, August 2013, Pages 978–991, <u>https://doi.org/10.1093/ije/dys112</u> ² Bird, P.K., McEachan, R.R.C., Mon-Williams, M. et al. Growing up in Bradford: protocol for the age 7–11 follow up of the Born in Bradford birth cohort. BMC Public Health 19, 939 (2019). <u>https://doi.org/10.1186/s12889-019-7222-2</u>
Acknowledgements	Born in Bradford has received funding from the Wellcome Trust [101597/Z/13/Z and 223601/Z/21/Z]; a joint grant from the UK Medical Research Council (MRC) and UK Economic and Social Science Research Council (ESRC) [MR/N024391/1; a British Heart Foundation Clinical Study grant [CS/16/4/32482]; the National Institute for Health Research under its Applied Research Collaboration Yorkshire and Humber [NIHR200166]; and a Health Foundation COVID-19 Award [2301201]. Born in Bradford is only possible because of the enthusiasm and commitment of the Children and Parents in BiB. We are grateful to all the participants, health professionals, schools and researchers who have made Born in Bradford happen.
	NMR metabolomics data – additional acknowledgement Researchers who use the NMR metabolomics data should cite the following data note: https://wellcomeopenresearch.org/articles/5-264 The funding acknowledgement should be: Funding for the metabolomics analyses in BiB has been provided by the US National Institutes of Health [R01 DK10324]; the European Research Council (ERC) under the European Union's Seventh Framework Programme [FP7/2007-2013] / ERC grant agreement no 669545; and the UK Medical Research Council [MC_UU_00011/6].
Ethics	Study: Born in Bradford Age of Wonder: a co-produced mixed methods longitudinal exploration of health and wellbeing trajectories through adolescence and young adulthood in the multi-cultural city of Bradford, UK. REC: 21/YH/0261 Study: Born in Bradford's Growing up Family Study REC: 16/YH/0320

	Study: Born in Bradford: A longitudinal cohort study of babies born in Bradford and their mothers and fathers REC: 07/H1302/112
Website for Data Requests	https://www.borninbradford.nhs.uk

ELSA: English Longitudinal Study o	f Ageing
Description of Study Population (including citations and references if required)	The English Longitudinal Study of Ageing (ELSA) is a unique and rich resource of information on the dynamics of health, social, wellbeing and economic circumstances in the English population aged 50 and older ¹ .
	The original sample was drawn from households that had previously responded to the Health Survey for England (HSE) between 1998 and 2001. The main fieldwork began in March 2002. The same group of respondents have been interviewed at two-yearly interviews.
	¹ Banks J, Batty GD, Breedvelt JJF, Coughlin K, Crawford R, Marmot M, Nazroo J, Oldfield Z, Steel N, Steptoe A, Wood M, Zaninotto P (2021) English Longitudinal Study of Ageing: Waves 0-9, 1998-2019
Acknowledgements	The English Longitudinal Study of Ageing was developed by a team of researchers based at University College London, NatCen Social Research, the Institute for Fiscal Studies, the University of Manchester and the University of East Anglia. The data were collected by NatCen Social Research. The funding is currently provided by the National Institute on Aging (Ref: R01AG017644) and by a consortium of UK government departments: Department for Health and Social Care; Department for Transport; Department for Work and Pensions, which is coordinated by the National Institute for Health Research (NIHR, Ref: 198-1074). Funding has also been provided by the Economic and Social Research Council (ESRC).
Ethics	https://www.elsa-project.ac.uk/ethical-approval

Website for Data Requests <u>http</u>	s://www.elsa-project.ac.uk/data-and-documentation

Description of Study Population	EVCEED is a longitudinal nonulation based sobort which
	EXCEED is a longitudinal population-based cohort which
(including citations and	facilitates investigation of genetic, environmental and
references if required)	lifestyle-related determinants of a broad range of diseases
	and of multiple morbidity through data collected at baseline
	and via electronic healthcare record linkage. Recruitment has
	taken place in Leicester, Leicestershire and Rutland since
	2013 and is ongoing, with 11,000 participants. Recruitment
	was widened to anyone over 18 years of age living in the
	Midlands in 2020. Participants provided a DNA sample, have
	consented to follow-up for up to 25 years through electronic
	health records and additional bespoke data collection is
	planned. Data available includes baseline demographics,
	anthropometry, spirometry, lifestyle factors (smoking and
	alcohol use) and longitudinal health information from
	primary care records, with additional linkage to other EHR
	datasets planned. Patients have consented to be contacted
	for recall-by-genotype and recall-by-phenotype sub-studies.
	Further details about the study can be accessed in the Cohort
	Profile Paper ¹ , with additional information about our COVID-
	19 Focus available as a Data Note Paper ²
	¹ Catherine John, Nicola F Reeve, Robert C Free, [] Edward J
	Hollox, Louise V Wain, Martin D Tobin. Cohort Profile:
	Extended Cohort for E-health, Environment and DNA
	(EXCEED). International Journal of Epidemiology, Volume 48,
	Issue 3, June 2019, Pages 678–679j,
	https://doi.org/10.1093/ije/dyz073
	² Lee PH, Guyatt AL, John C et al. Extended Cohort for E-
	health, Environment and DNA (EXCEED) COVID-19 focus
	[version 1; peer review: awaiting peer review]. Wellcome
	Open Res 2021, 6:349,
	https://doi.org/10.12688/wellcomeopenres.17437.1

Acknowledgements	EXCEED is funded by the University of Leicester, the NIHR Leicester Respiratory Biomedical Research Centre, the NIHR Clinical Research Network East Midlands, the Medical Research Council (grant G0902313) the Wellcome Trust (grant 202849) and HDR UK BREATHE- Health Data Research Hub for Respiratory Health (grant MC-PC_19004).
Ethics	The study is led by the University of Leicester, in partnership with University Hospitals of Leicester NHS Trust and in collaboration with Leicestershire Partnership NHS Trust, local general practices and smoking cessation services. Ethical approval for the study was obtained from the Leicester Central Research Ethics Committee (13/EM/0226).
Website for Data Requests	www.exceed.org.uk/research

Generation Scotland	
Description of Study Population (including citations and references if required)	The Generation Scotland Scottish Family Health Study has 24,000 adult volunteers recruited in Scotland 2006-2011, with consent for linkage to medical records and recontact for further studies ¹ . <u>www.ncbi.nlm.nih.gov/pubmed/?term=22786799</u> Smith, B. H., Campbell, A., Linksted, P., Fitzpatrick, B., Jackson, C., Kerr, S. M., Morris, A. D. (2013). Cohort Profile: Generation Scotland: Scottish Family Health Study (GS:SFHS). The study, its participants and their potential for genetic research on health and illness. International Journal of Epidemiology, 42(3), 689-700. <u>http://doi.org/10.1093/ije/dys084</u>
Acknowledgements	Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council

	[HR03006] and is currently supported by the Wellcome Trust [216767/Z/19/Z].
Ethics	Generation Scotland obtained Research Tissue Bank approval from the East of Scotland Research Ethics Service (on behalf of NHS Scotland). Reference number 20/ES/0021.
Website for Data Requests	www.generationscotland.org

GLAD: Genetic Links to Anxiety and	Depression Study dataset including the Eating Disorders
Genetics Initiative (EDGI) and Covid	1-19 Psychiatry and Neurological Genetics Study (COPING) study
Description of Study Population	The <u>Co</u> vid-19 <u>P</u> sychiatry and <u>N</u> eurological <u>G</u> enetics Study
(including citations and references	(COPING) was set up as a COVID-19 specific study investigating
if required)	the mental health impact of individuals living in the UK
	(N=30,450). COPING participants were recruited from the
	existing GLAD, EDGI and NIHR Bioresource studies to provide
	pandemic relevant data. – for full details, see below – Young et
	al. (2021).
	The Genetic Links to Anxiety and Depression (GLAD) Study is an
	NIHR Bioresource funded project assessing the genetic and
	environmental links to anxiety and depression (N=30,318) ¹ .
	The Eating Disorders Genetics Initiative (EDGI) study is an NIHR
	Bioresource funded project assessing the genetic and
	environmental links to all eating disorders (N=3973).
	GLAD –
	¹ Davies, M. R., Kalsi, G., Armour, C., Jones, I. R., McIntosh, A. M.,
	Smith, D. J., & Breen, G. (2019). The Genetic Links to Anxiety
	and Depression (GLAD) Study: Online recruitment into the
	largest recontactable study of depression and
	anxiety. Behaviour Research and Therapy, 123, 103503.

	COPING –
	Young, K. S., Purves, K. L., Hübel, C., Davies, M. R., Thompson, K. N., Bristow, S., & Breen, G. (2021). Depression, anxiety and PTSD symptoms before and during the COVID-19 pandemic in the UK.
	EDGI –
	N/A
Acknowledgements	The NIHR BioResource Centre Maudsley and the NIHR BioResource should be acknowledged in all publications resulting from any study that we have supported. Please use the following wording:
	We thank the [delete as appropriate] GLAD/EDGI/COPING and [always keep] NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource centres, NHS Trusts and staff for their contribution. We thank the National Institute for Health Research, NHS Blood and Transplant, and Health Data Research UK as part of the Digital Innovation Hub Programme. This work was supported by the National Institute of Health Research (NIHR) BioResource Centre Maudsley and is part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. Patient and public involvement groups and services were provided by the NIHR KCL-Maudsley Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
	Any publication that makes substantial use of the data/participants provided by the GLAD Study should cite the following authors.
	NIHR BioResource Consortium
	Prof Gerome Breen

Prof Thalia Eley
Prof Matthew Hotopf
Prof Cherie Armour
Prof Andrew McIntosh
Prof Ian R Jones
Dr Gursharan Kalsi
Dr Molly Davies
Dr Alish Palmos
Dr Christopher Huebel
Henry Rogers
Dina Monssen
Monika McAtarsney-Kovacs
Shannon Bristow
lan Marsh
Kiran Glen
Chelsea Mika Malouf
Saakshi Kakar
Emily Kelly
Steven Bright
Affiliations: NIHR BioResource Centre Maudsley, King's College London, Denmark Hill, De Crespigny Park, London SE5 8AF
Centre for Social, Developmental and Psychiatric Genetics, IoPPN, King's College London, Denmark Hill, De Crespigny Park, London SE5 8AF
Any publication that makes substantial use of the data/participants provided by the EDGI Study should cite the following authors.

	NIHR BioResource Consortium
	Prof Gerome Breen
	Prof Thalia Eley
	Prof Janet Treasure
	Dr Moritz Herle
	Dr Gursharan Kalsi
	Dr Molly Davies
	Dr Christopher Huebel
	Dr Alish Palmos
	Henry Rogers
	Dina Monssen
	Monika McAtarsney-Kovacs
	Shannon Bristow
	lan Marsh
	Kiran Glen
	Chelsea Mika Malouf
	Helena Davies
	Emily Kelly
	Saakshi Kakar
	Affiliations: NIHR BioResource Centre Maudsley, King's College London, Denmark Hill, De Crespigny Park, London SE5 8AF
	Centre for Social, Developmental and Psychiatric Genetics,
	IoPPN, King's College London, Denmark Hill, De Crespigny Park, London SE5 8AF
Ethics	GLAD – 18/LO/1218 – London Fulham REC
	EDGI – 19/LO/1254 – London Fulham REC
	COPING – 20/SW/0078 – South West Central Bristol REC

Website for Data Requests	https://gladstudy.org.uk (changing Autumn 2022)
	https://edgiuk.org

MCS: Millennium Cohort Study	
Description of Study Population (including citations and references if required)	The Millennium Cohort Study (MCS) is following the lives of young people born across England, Scotland, Wales and Northern Ireland in 2000-02. The study began with an original sample of 18,818 cohort members. The study is designed and led by the Centre for Longitudinal Studies (CLS) at University College London.
	The broad aim of the study is to examine the impact that circumstances and experiences at one stage of life have on outcomes and achievements in later life. Since the baseline survey at age 9 months, there have been six major 'sweeps' at ages 3, 5, 7, 11, 14 and 17. The next sweep, at age 22, is currently under development.
	Data have been collected from a number of different sources, including the cohort members and their parents and teachers. The data have been collected in a variety of ways, including via paper and electronic questionnaires, biological samples, physical measurements, tests of ability, and linked educational attainment and health records.
	The information collected forms a high quality data resource for scientific investigations across a full range of domains of individuals' lives and across different points in time in them. The study has been designed to ensure comparability with other major cohort studies both in the UK and internationally and to permit the examination of links between social change and the changing experiences of different cohorts.
	https://www.llcsjournal.org/index.php/llcs/article/view/410/0
	https://academic.oup.com/ije/article/43/6/1719/703283
Acknowledgements	MCS is core-funded by the ESRC and co-funded by a consortium of government departments.

Ethics	Ethics approval has been obtained for each follow-up from an NHS Research Ethics Committee (REC). In addition, separate REC approval is in place to cover the ongoing activities of the study in between major sweeps of data collection (i.e. Keeping in touch with and tracing cohort Members; cleaning, documenting and providing access to the data for research and linking data from administrative sources to survey data to
	and linking data from administrative sources to survey data to increase the utility of the data for research.
Website for Data Requests	https://cls.ucl.ac.uk/cls-studies/mcs/

NCDS: National Child Development Study	
Description of Study Population (including citations and references if required)	The National Child Development Study (NCDS) is a continuing longitudinal study that seeks to follow the lives of all those living in Great Britain who were born in one particular week in 1958. Conducted by the Centre for Longitudinal Studies , the aim of the study is to improve understanding of the factors affecting human development over the whole lifespan. It collects information on physical and educational development, economic circumstances, employment, family life, health behaviour, wellbeing, social participation and attitudes.
	The broad aim of the study is to examine the impact that circumstances and experiences at one stage of life have on outcomes and achievements in later life. Since the birth survey in 1958, there have been ten 'sweeps' of all cohort members at ages 7, 11, 16, 23, 33, 42, 44/5 (a biomedical collection) 46, 50 and most recently at 55. The Age 62 Sweep is currently in the field (2022).
	Data have been collected from a number of different sources, including the midwife present at birth, parents of the cohort members, teachers, doctors and the cohort members themselves. The data have been collected in a variety of ways, including via paper and electronic questionnaires, clinical records, medical examinations, biological samples, physical measurements, tests of ability and educational assessments.
	The information collected forms a high quality data resource for scientific investigations across a full range of domains of individuals' lives and across different points in time in them. The study has been designed to ensure comparability with other major cohort studies and to permit the examination of links between social change and the changing experiences of different cohorts.
	https://cls.ucl.ac.uk/cls-studies/1958-national-child- development-study/

Acknowledgements	NCDS is core-funded by the ESRC.
Ethics	Ethics approval has been obtained for each follow-up from an NHS Research Ethics Committee (REC) since 2000. In addition, separate REC approval is in place to cover the ongoing activities of the study in between major sweeps of data collection (i.e. Keeping in touch with and tracing cohort members; cleaning, documenting and providing access to the data for research; and linking data from administrative sources to survey data to increase the utility of the data for research).
Website for Data Requests	https://cls.ucl.ac.uk/cls-studies/ncds/

Next Steps	
Description of Study Population (including citations and references if required)	Next Steps (previously known as the Longitudinal Study of Young People in England (LSYPE1)) is a major longitudinal study that follows the lives of around 16,000 people born in 1989-90. The first seven sweeps of the study (2004-2010) were funded and managed by the Department for Education and mainly focused on the educational and early labour market experiences of young people.
	The study began in 2004 and included young people in Year 9 who attended state and independent schools in England. Following the initial survey at age 13-14, the cohort members were interviewed every year until 2010.
	In 2013 the management of Next Steps was transferred to the Centre for Longitudinal Studies (CLS) at the IOE, UCL's Faculty of Education and Society. The first sweep conducted by CLS aimed to find out how the lives of the cohort members had turned out at age 25. It maintained the strong focus on education, but the content was broadened to become a more multi-disciplinary research resource.
	The Age 32 Sweep is currently in the field (2022).

	in between major sweeps of data collection (i.e. keeping in touch with and tracing cohort members; cleaning, documenting and providing access to the data for research; and linking data from administrative sources to survey data to increase the utility of the data for research).
Ethics	Ethics approval is obtained for each follow-up from an NHS Research Ethics Committee (REC). In addition, separate REC approval is in place to cover the ongoing activities of the study
Acknowledgements	Next Steps now is core-funded by the ESRC.
	https://cls.ucl.ac.uk/cls-studies/next-steps/
	https://doc.ukdataservice.ac.uk/doc/5545/mrdoc/pdf/nextsters_age25_survey_user_guide_v3.pdf
	https://doc.ukdataservice.ac.uk/doc/5545/mrdoc/pdf/next_s ps_userguide_to_the_redeposit_of_sweeps_1to7_may2020.p f

NICOLA: Northern Ireland Cohort for the Longitudinal Study of Ageing	
Description of Study Population	NICOLA is a large-scale longitudinal study in Northern Ireland
(including citations and references	designed to investigate ageing.
if required)	
	Set up in 2013 the study visited households where at least one
	member was <a>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
	representative sample of 8478 men and women living in private
	residential accommodation in Northern Ireland.

	Wave 1 Data collection involved four components; a computer assisted face-to-face home interview, a self-completion questionnaire, a health assessment (during which blood and urine samples were collected) and subsequently a dietary questionnaire.
	The participants who consented to follow up for Wave 2 were asked to complete a 2 nd home survey and self-completion questionnaire approximately 3.5 years later. From these participants 5925 did not opt-out of additional linkage and were therefore in addition mailed a Covid questionnaire (3149 completed)
	Neville CE, Cruise SM; Burns F. (2019). The Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA). In Gu D, Dupre M. (Ed.), Encyclopedia of Gerontology and Population Aging Cham: Springer.
Acknowledgements	We are grateful to all the participants of the NICOLA Study, and the whole NICOLA team.
	The study has received funding from The Atlantic Philanthropies, the Economic and Social Research Council, the UKCRC Centre of Excellence for Public Health Northern Ireland, the Centre for Ageing Research and Development in Ireland, the Office of the First Minister and Deputy First Minister, HSC Research and Development Division of the Public Health Agency, the Wellcome Trust/Wolfson Foundation and Queen's University Belfast which provide core financial support for NICOLA. The authors alone are responsible for the interpretation of the data and any views or opinions presented are solely those of the authors and do not necessarily represent those of the NICOLA Study team.
Ethics	Ethical approval for NICOLA was obtained from the School of Medicine, Dentistry and Biomedical Sciences Ethics Committee, Queen's University Belfast.

Website for Data Requests	https://www.qub.ac.uk/sites/NICOLA/InformationforResearchers/

NIHR BioResource: National Institute of Health Research BioResource COVID-19 Psychiatry and Neurological Genetics (COPING) Study

Description of Study Population	The NIHR BioResource is a recallable resource of over 200,000
(including citations and references	volunteers from the general population, and patients with rare
if required)	and common diseases. Participants provide information about
	their health and lifestyle, together with biological samples,
	including DNA, and consent for access to their health records
	and for re-contact. The BioResource is one of four key
	infrastructures supporting population level genomic projects in
	the UK Life Science Industrial Strategy. Key unique features of
	the NIHR BioResource are its focus on recall of participants for
	experimental medicine studies by genotype and/or phenotype,
	and the inclusion of both healthy volunteers and patients with
	common and rare diseases. Participants represented in UK LLC
	are respondents to an online recall study, the Covid-19
	Psychiatry and Neurological Genetics (COPING) study ¹ .
	1 https://www.maudalauhra.nihr.ac.uk/pacts/2020/mau/cauid
	¹ <u>https://www.maudsleybrc.nihr.ac.uk/posts/2020/may/covid-</u>
	19-psychiatry-and-neurological-genetics-coping-study/
Acknowledgements	We thank NIHR BioResource volunteers for their participation,
Acknowledgements	and gratefully acknowledge NIHR BioResource centres, NHS
	Trusts and staff for their contribution. We thank the National
	Institute for Health and Care Research, NHS Blood and
	Transplant, and Health Data Research UK as part of the Digital
	Innovation Hub Programme. The views expressed are those of
	the author(s) and not necessarily those of the NHS, the NIHR or
	the Department of Health and Social Care.
Ethics	Research Tissue Bank (REC REF: 17/EE/0025).
Website for Data Requests	https://bioresource.nihr.ac.uk/using-our-bioresource/academic-
	and-clinical-researchers/apply-for-bioresource-data/

TRACK-COVID Study

Description of Study Population	The study employed a two-stage design. During the first stage
(including citations and references if required)	of this effort, ~90,000 individuals previously recruited into the INTERVAL ¹ , COMPARE ² and STRIDES studies (i.e., National Blood Donor Studies ³) were invited via email to participate and to provide Covid-19-related information using an online questionnaire. During the second stage, participants were asked to provide self-collected finger-prick capillary blood sample every 6 weeks over a period of 18 months.
	¹ Di Angelantonio E, Thompson SG, Kaptoge SK, Moore C, Walker M, Armitage J, Ouwehand WH, Roberts DJ, Danesh J, INTERVAL Trial Group. Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors. Lancet. 2017 Nov 25;390(10110):2360- 2371.
	² Bell S, Sweeting M, Ramond A, Chung R, Kaptoge S, Walker M, Bolton T, Sambrook J, Moore C, McMahon A, Fahle S, Cullen D, Mehenny S, Wood AM, Armitage J, Ouwehand WO, Miflin G, Roberts DJ, Danesh J, Di Angelantonio E, COMPARE Study Group. Comparison of four methods to measure haemoglobin concentrations in whole blood donors (COMPARE): A diagnostic accuracy study. Transfus Med. 2020 Dec 20. ³ <u>http://www.donorhealth-btru.nihr.ac.uk/</u>
Acknowledgements	The TRACK-COVID study recruited participants from the INTERVAL trial and the COMPARE study and the academic coordinating centre would like to thank blood donor centre staff and blood donors for their participation. The centre was supported by core funding from the: National Institute for Health and Care Research (NIHR) Blood and Transplant Research Unit (BTRU) in Donor Health and Genomics (NIHR BTRU-2014-10024), NIHR BTRU in Donor Health and Behaviour (NIHR203337), British Heart Foundation (RG/13/13/30194; RG/18/13/33946) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) [*].
	We thank NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource centres, NHS Trusts and staff for their contribution. We thank the NIHR, NHS

Blood and Transplant (NHSBT) and Health Data Research (HDR) UK as part of the Digital Innovation Hub Programme.
Participants in the COMPARE study were recruited with the active collaboration of NHSBT England (www.nhsbt.nhs.uk). Funding was provided by NHSBT and the NIHR BTRU in Donor Health and Genomics (NIHR BTRU-2014-10024). DNA extraction and genotyping were co-funded by the NIHR BTRU and the NIHR BioResource (http://bioresource.nihr.ac.uk). The academic coordinating centre for COMPARE was supported by core funding from the: NIHR BTRU in Donor Health and Genomics, UK MRC (MR/L003120/1), BHF (RG/13/13/30194; RG/18/13/33946) and NIHR Cambridge BRC (BRC-1215-20014) [*]. A complete list of the investigators and contributors to the COMPARE study is provided in reference [**]. The academic coordinating centre would like to thank blood donor centre staff and blood donors for participating in the COMPARE study.
Participants in the INTERVAL randomised controlled trial were recruited with the active collaboration of NHSBT, which has supported field work and other elements of the trial. DNA extraction and genotyping were co-funded by the NIHR, the NIHR BioResource and the NIHR Cambridge BRC (BRC-1215- 20014) [*]. The academic coordinating centre for INTERVAL was supported by core funding from the: NIHR BTRU in Donor Health and Genomics (NIHR BTRU-2014-10024), UK MRC (MR/L003120/1), BHF (SP/09/002; RG/13/13/30194; RG/18/13/33946) and NIHR Cambridge BRC (BRC-1215-20014) [*]. A complete list of the investigators and contributors to the INTERVAL trial is provided in reference [***]. The academic coordinating centre would like to thank blood donor centre staff and blood donors for participating in the INTERVAL trial.
This work was also supported by HDR UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health

	Agency (Northern Ireland), British Heart Foundation and Wellcome.
	We thank Leeds Teaching Hospitals NHS Foundation Trust for their contribution to the SARS-COV-2 antibody analysis.
	*The views expressed are those of the author(s) and not necessarily those of the NIHR, NHSBT or the Department of Health and Social Care.
	**Bell S, Sweeting M, Ramond A, Chung R, Kaptoge S, Walker M, Bolton T, Sambrook J, Moore C, McMahon A, Fahle S, Culler D, Mehenny S, Wood AM, Armitage J, Ouwehand WO, Miflin G Roberts DJ, Danesh J, Di Angelantonio E, COMPARE Study Group. Comparison of four methods to measure haemoglobin concentrations in whole blood donors (COMPARE): A diagnostic accuracy study. Transfus Med. 2020 Dec 20.
	***Di Angelantonio E, Thompson SG, Kaptoge SK, Moore C, Walker M, Armitage J, Ouwehand WH, Roberts DJ, Danesh J, INTERVAL Trial Group. Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors. Lancet. 2017 Nov 25;390(10110):2360- 2371.
Ethics	20/EM/0121 - East Midlands - Nottingham 2 Research Ethics Committee
Website for Data Requests	http://www.donorhealth-btru.nihr.ac.uk/

TwinsUK	
Description of Study Population	TwinsUK is the largest adult twin registry in the UK and the
(including citations and references	most clinically detailed in the world. The national, population-
if required)	based study was founded in 1992 and aims to investigate the
	genetic and environmental basis of a range of complex diseases
	and conditions. TwinsUK currently consists of over 15,700
	volunteer adult twins (both monozygotic and dizygotic) who
	are between 18 to 104 years of age from around the UK (mean

	age 59) ¹ . The cohort is predominantly female, and disease prevalence is broadly reflective of the UK population. Over 700,000 biological samples and extensive phenotypes have been collected longitudinally over 30 years.
	¹ Verdi S, Abbasian G, Bowyer RCE, et al.: TwinsUK: The UK Adult Twin Registry Update. Twin Res Hum Genet. 2019; 22(6): 523–529.
Acknowledgements	We thank TwinsUK members for their participation and the TwinsUK operations team for coordinating and undertaking twin clinic visits and data and sample collections.
	TwinsUK is funded by the Wellcome Trust, Medical Research Council, Versus Arthritis, European Union Horizon 2020, Chronic Disease Research Foundation (CDRF), Zoe Ltd, the National Institute for Health and Care Research (NIHR) Clinical Research Network (CRN) and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London.
Ethics	All collections of TwinsUK data have received ethical approval associated with TwinsUK Biobank (19/NW/0187), TwinsUK (EC04/015) or Healthy Ageing Twin Study (H.A.T.S) (07/H0802/84) from NHS Research Ethics Committees. Linkage to health and environmental records is also covered by approval from the Health Research Authority (19/CAG/0223).
Website for Data Requests	https://twinsuk.ac.uk/resources-for-researchers/access-our- data/

Understanding Society – the UK Household Longitudinal Study	
Description of Study Population	Understanding Society, the UK Household Longitudinal Study, is
(including citations and references	a longitudinal survey of the members of ~40,000 households (at
if required)	Wave 1, 2009-10) in the United Kingdom. The survey sample
	consists of a large General Population Sample (~26,000

	households) plus three other components: the Ethnic Minority Boost Sample (~4,000 households), the former British Household Panel Survey sample (~8,000 households) and the Immigrant and Ethnic Minority Boost Sample (~2,900 households, added at Wave 6). Household and individual interviews are conducted annually. The study is multi-topic and multi-purpose.
	From April 2020 to September 2021, participants from the main Understanding Society sample were asked to complete nine short web-surveys (with a telephone option in some months). The COVID-19 study covered the changing impact of the pandemic on the welfare of UK individuals, families and wider communities. ~18,000 individuals provided a full or partial interview at Wave 1 (April 2020).
	At Wave 8 of the COVID-19 study, 8477 participants provided consent to link their survey data to administrative health records.
Acknowledgements	Understanding Society is an initiative funded by the Economic and Social Research Council and various Government Departments, with scientific leadership by the Institute for Social and Economic Research, University of Essex, and survey delivery by NatCen Social Research and Kantar Public
	The COVID-19 study (2020-2021) was funded by the Economic and Social Research Council and the Health Foundation. Serology testing was funded by the COVID-19 Longitudinal Health and Wealth – National Core Study. Fieldwork for the web survey was carried out by Ipsos MORI and for the telephone survey by Kantar.
Ethics	The University of Essex Ethics Committee has approved all data collection on Understanding Society main study, COVID-19 surveys and innovation panel waves, including asking consent for all data linkages except to health records.

	Approval for asking consent for health record linkage and for the collection of blood and subsequent serology testing in the March 2021 wave of the COVID-19 study was obtained from London – City & East Research Ethics Committee (21/HRA/0644).
Website for Data Requests	https://ukllc.ac.uk or https://ukdataservice.ac.uk